

Supplementary Material

1 Supplementary Table

Supplementary Table 1. Gene targets of Fuzi

ID	Name	Target	Symbol
MOL002211	11,14-eicosadienoic acid	Nuclear receptor coactivator 2	NCOA2
MOL002388	Delphin_qt	Prostaglandin G/H synthase 1	PTGS1
MOL002388	Delphin_qt	Prostaglandin G/H synthase 2	PTGS2
MOL002388	Delphin_qt	Nuclear receptor coactivator 2	NCOA2
MOL002392	Deltoin	Prostaglandin G/H synthase 1	PTGS1
MOL002392	Deltoin	Sodium channel protein type 5 subunit alpha	SCN5A
MOL002392	Deltoin	Prostaglandin G/H synthase 2	PTGS2
MOL002392	Deltoin	Acetylcholinesterase	ACHE
MOL002392	Deltoin	Alpha-1B adrenergic receptor	ADRA1B
MOL002392	Deltoin	Beta-2 adrenergic receptor	ADRB2
MOL002392	Deltoin	Trypsin-1	PRSS1
MOL002395	Deoxyandrographolide	Prostaglandin G/H synthase 2	PTGS2
MOL002395	Deoxyandrographolide	Progesterone receptor	PGR

Supplementary Material

MOL002395	Deoxyandrographolide	Nuclear receptor coactivator 2	NCOA2
MOL002395	Deoxyandrographolide	Nuclear receptor coactivator 1	NCOA1
MOL002398	Karanjin	Prostaglandin G/H synthase 1	PTGS1
MOL002398	Karanjin	Estrogen receptor	ESR1
MOL002398	Karanjin	Prostaglandin G/H synthase 2	PTGS2
MOL002398	Karanjin	Serine/threonine-protein kinase Chk1	CHEK1
MOL000359	sitosterol	Progesterone receptor	PGR
MOL000359	sitosterol	Nuclear receptor coactivator 2	NCOA2
MOL000359	sitosterol	Mineralocorticoid receptor	NR3C2

Supplementary Table 2. Gene targets of Banxia

ID	Name	Target	Symbol
MOL000358	beta-sitosterol	Serum paraoxonase/arylesterase 1	PON1
MOL000519	coniferin	Estrogen receptor	ESR1
MOL002714	baicalein	Androgen receptor	AR
MOL000519	coniferin	Androgen receptor	AR

MOL006957	(3S,6S)-3-(benzyl)-6-(4-hydroxybenzyl)piperazine-2,5-quinone	Androgen receptor	AR
MOL002714	baicalein	Cytochrome c	CYCS
MOL002714	baicalein	Vascular endothelial growth factor A	VEGFA
MOL002670	cavidine	Prostaglandin G/H synthase 1	PTGS1
MOL002714	baicalein	Prostaglandin G/H synthase 1	PTGS1
MOL000358	beta-sitosterol	Prostaglandin G/H synthase 1	PTGS1
MOL000449	stigmasterol	Prostaglandin G/H synthase 1	PTGS1
MOL005030	gondoic acid	Prostaglandin G/H synthase 1	PTGS1
MOL006936	10,13-eicosadienoic	Prostaglandin G/H synthase 1	PTGS1
MOL000519	coniferin	Peroxisome proliferator activated receptor gamma	PPARG
MOL002714	baicalein	Apoptosis regulator Bcl-2	BCL2
MOL000358	beta-sitosterol	Apoptosis regulator Bcl-2	BCL2
MOL002670	cavidine	Muscarinic acetylcholine receptor M5	CHRM5
MOL002714	baicalein	Trypsin-1	PRSS1
MOL002670	cavidine	5-hydroxytryptamine receptor 3A	HTR3A

Supplementary Material

MOL002670	cavidine	Coagulation factor VII	F7
MOL002670	cavidine	Alpha-2C adrenergic receptor	ADRA2C
MOL002670	cavidine	Muscarinic acetylcholine receptor M4	CHRM4
MOL000358	beta-sitosterol	Muscarinic acetylcholine receptor M4	CHRM4
MOL002670	cavidine	Muscarinic acetylcholine receptor M3	CHRM3
MOL000358	beta-sitosterol	Muscarinic acetylcholine receptor M3	CHRM3
MOL000449	stigmasterol	Muscarinic acetylcholine receptor M3	CHRM3
MOL000519	coniferin	Muscarinic acetylcholine receptor M3	CHRM3
MOL000358	beta-sitosterol	Alpha-1A adrenergic receptor	ADRA1A
MOL000449	stigmasterol	Alpha-1A adrenergic receptor	ADRA1A
MOL002714	baicalein	Cellular tumor antigen p53	TP63
MOL000449	stigmasterol	Chymotrypsinogen B	CTRB1
MOL001755	24-ethylcholest-4-en-3-one	Progesterone receptor	PGR
MOL000358	beta-sitosterol	Progesterone receptor	PGR

MOL000449	stigmasterol	Progesterone receptor	PGR
MOL000358	beta-sitosterol	Muscarinic acetylcholine receptor M2	CHRM2
MOL000449	stigmasterol	Muscarinic acetylcholine receptor M2	CHRM2
MOL002714	baicalein	Aryl hydrocarbon receptor	AHR
MOL002714	baicalein	Nuclear receptor coactivator 1	NCOA1
MOL000449	stigmasterol	Nuclear receptor coactivator 1	NCOA1
MOL000519	coniferin	Nuclear receptor coactivator 1	NCOA1
MOL002714	baicalein	Nuclear receptor coactivator 2	NCOA2
MOL000358	beta-sitosterol	Nuclear receptor coactivator 2	NCOA2
MOL000449	stigmasterol	Nuclear receptor coactivator 2	NCOA2
MOL005030	gondoic acid	Nuclear receptor coactivator 2	NCOA2
MOL000519	coniferin	Nuclear receptor coactivator 2	NCOA2
MOL006936	10,13-eicosadienoic	Nuclear receptor coactivator 2	NCOA2
MOL002670	cavidine	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	PDE10A
MOL001755	24-ethylcholest-4-en-3-one	Mineralocorticoid receptor	NR3C2

Supplementary Material

MOL000449	Stigmasterol	Mineralocorticoid receptor	NR3C2
MOL003578	Cycloartenol	Mineralocorticoid receptor	NR3C2
MOL000358	beta-sitosterol	Neuronal acetylcholine receptor subunit alpha-2	CHRNA2
MOL000449	stigmasterol	Aldose reductase	AKR1B1
MOL000358	beta-sitosterol	Gamma-aminobutyric acid receptor subunit alpha-1	GABRA1
MOL000449	stigmasterol	Gamma-aminobutyric acid receptor subunit alpha-1	GABRA1
MOL002670	cavidine	Retinoic acid receptor RXR-beta	RXRB
MOL002714	baicalein	Transcription factor p65	RELA
MOL002714	baicalein	Proto-oncogene c-Fos	FOS
MOL002714	baicalein	Caspase-3	CASP3
MOL002714	baicalein	Hypoxia-inducible factor 1-alpha	HIF1A
MOL002714	baicalein	Fos-related antigen 1	FOSL1
MOL002714	baicalein	G2/mitotic-specific cyclin-B1	CCNB1
MOL002714	baicalein	Insulin-like growth factor II	IGF2
MOL002714	baicalein	NADPH oxidase 5	NOX5

MOL002714	baicalein	Apolipoprotein D	APOD
MOL000358	beta-sitosterol	Caspase-9	CASP9
MOL000358	beta-sitosterol	Caspase-3	CASP3
MOL000358	beta-sitosterol	Caspase-8	CASP8
MOL000358	beta-sitosterol	Protein kinase C alpha type	PRKCA

Supplementary Table 3. Number of targets corresponding to different components

Source	MolName	count
Banxia	baicalein	19
Banxia	beta-sitosterol	15
Banxia	Stigmasterol	11
Banxia	Cavidine	9
Banxia	coniferin	6
Banxia	gondoic acid	2
Banxia	10,13-eicosadienoic	2
Banxia	24-Ethylcholest-4-en-3-one	2
Banxia	(3S,6S)-3-(benzyl)-6-(4-hydroxybenzyl)piperazine-2,5-quinone	1

Supplementary Material

Banxia	Cycloartenol	1
Fuzi	Deltoin	7
Fuzi	Deoxyandrographolide	4
Fuzi	Karanjin	4
Fuzi	Delphin_qt	3
Fuzi	sitosterol	3
Fuzi	11,14-eicosadienoic acid	1

Supplementary Table 4. The data of GO enrichment analysis

ID	Description	BgRatio	pvalue	p-adjust	qvalue	geneID	Count
GO:0033613	transcription factor-binding	64/16969	1.77E-06	0.00017363	5.78E-05	2353/5468/5970	3
GO:0046982	protein heterodimerization-activity	497/16969	2.37E-05	0.001162372	0.00038704122	2353/5468/5970/74	4
GO:0042805	actinin-binding	29/16969	5.89E-05	0.001924371	0.000640768	5468/5970	2
GO:0004879	nuclear-receptor activity	46/16969	0.000149674	0.002933612	0.00097682	5468/5241	2
GO:0098531	transcription factor activity, direct ligand regulated sequence-specific-DNA binding	46/16969	0.000149674	0.002933612	0.00097682	5468/5241	2
GO:0003707	steroid hormone receptor activity	54/16969	0.000206615	0.003374718	0.001123698	5468/5241	2
GO:0001228	DNA-binding transcription activator	390/16969	0.000393637	0.005510923	0.001835001	2353/5970/5241	3

批注 [倪1]: Dear editors, to show the tables clearly, we insert the link instead of the tables.

	activity, RNA polymerase II-specific						
	RNA polymerase II proximal promoter sequence-specific DNA binding						
GO:0000978		432/16969	0.000531383	0.005945268	0.001979627	5468/5970/5241	\$
GO:0003682	chromatin binding	437/16969	0.000549598	0.005945268	0.001979627	2353/5468/5970	\$
GO:0000987	proximal promoter sequence-specific DNA binding	452/16969	0.00060666	0.005945268	0.001979627	5468/5970/5241	\$
GO:0005126	cytokine receptor-binding	210/16969	0.00307269	0.027374547	0.009115048	836/7422	2
GO:0005172	vascular endothelial growth factor receptor-binding	11/16969	0.004529671	0.02971968	0.009895919	7422	+
GO:0016004	phospholipase activator-activity	11/16969	0.004529671	0.02971968	0.009895919	836	+
GO:0004861	cyclin-dependent protein serine/threonine kinase-inhibitor activity	12/16969	0.004940585	0.02971968	0.009895919	836	+
GO:0004953	icosanoid receptor-activity	12/16969	0.004940585	0.02971968	0.009895919	5468	+
GO:0042301	phosphate-ion binding	12/16969	0.004940585	0.02971968	0.009895919	5970	+
GO:0060229	lipase-activator activity	13/16969	0.005351355	0.02971968	0.009895919	836	+
GO:0005161	platelet-derived growth factor receptor-binding	14/16969	0.005761979	0.02971968	0.009895919	7422	+
GO:0036041	long-chain fatty acid-binding	14/16969	0.005761979	0.02971968	0.009895919	5468	+
GO:0046965	retinoid-X receptor-binding	15/16969	0.006172457	0.030245042	0.010070852	5468	+
GO:0005123	death-receptor binding	17/16969	0.006992979	0.031171061	0.010379193	836	+

Supplementary Material

GO:0016538	cyclin-dependent protein serine/threonine kinase-regulator activity	18/16969	0.007403022	0.031171061	0.010379193	836	1
GO:0004190	aspartic-type endopeptidase activity	20/16969	0.008222673	0.031171061	0.010379193	836	1
GO:0000979	RNA polymerase-II core-promoter sequence-specific-DNA binding	21/16969	0.00863228	0.031171061	0.010379193	2353	1
GO:0001223	transcription coactivator binding	21/16969	0.00863228	0.031171061	0.010379193	5970	1
GO:0051393	alpha-actinin binding	21/16969	0.00863228	0.031171061	0.010379193	5468	1
GO:0070001	aspartic-type peptidase activity	22/16969	0.009041743	0.031171061	0.010379193	836	1
GO:0070412	R-SMAD binding	23/16969	0.009451061	0.031171061	0.010379193	2353	1
GO:1901567	fatty-acid derivative binding	23/16969	0.009451061	0.031171061	0.010379193	5468	1
GO:0001968	fibronectin binding	24/16969	0.009860234	0.031171061	0.010379193	7422	1
GO:0042974	retinoic-acid receptor-binding	24/16969	0.009860234	0.031171061	0.010379193	5468	1
GO:0005504	fatty-acid binding	28/16969	0.011495477	0.034311314	0.01142482	5468	1
GO:0042056	chemoattractant activity	29/16969	0.011903925	0.034311314	0.01142482	7422	1
GO:0051059	NF-kappaB binding	29/16969	0.011903925	0.034311314	0.01142482	5970	1
GO:0030291	protein serine/threonine kinase-inhibitor activity	30/16969	0.01231223	0.034474243	0.011479071	836	1
GO:0001046	core-promoter sequence-	32/16969	0.013128404	0.035738433	0.011900015	2353	1

	specific-DNA binding						
	RNA						
GO:0001102	polymerase-II activating transcription factor-binding	37/16969	0.0151663 12	0.0401631 34	0.0133733 31	2353	+
GO:0001221	transcription cofactor-binding	38/16969	0.0155734 6	0.0401631 34	0.0133733 31	5970	+
GO:0030331	estrogen receptor-binding	41/16969	0.0167940 39	0.0419792 36	0.0139780 49	5468	+
GO:0001047	core-promoter binding	42/16969	0.0172006 11	0.0419792 36	0.0139780 49	2353	+
GO:0050840	extracellular matrix-binding	43/16969	0.0176070 38	0.0419792 36	0.0139780 49	7422	+
GO:0030374	nuclear-receptor transcription coactivator activity	45/16969	0.0184194 61	0.0419792 36	0.0139780 49	5468	+
GO:0032813	tumor-necrosis factor-receptor superfamily binding	45/16969	0.0184194 61	0.0419792 36	0.0139780 49	836	+
GO:0004722	protein serine/threonine phosphatase activity	49/16969	0.0200425 78	0.0436482 82	0.0145337 99	54205	+
GO:0070888	E-box-binding	49/16969	0.0200425 78	0.0436482 82	0.0145337 99	5468	+
GO:0004197	cysteine-type endopeptidase activity	56/16969	0.0228774 99	0.0477020 19	0.0158835 94	836	+
GO:0043621	protein-self- association	56/16969	0.0228774 99	0.0477020 19	0.0158835 94	5468	+
GO:0033293	monocarboxylic acid-binding	59/16969	0.0240903 11	0.0480088 18	0.0159857 5	5468	+
GO:0070491	repressing transcription factor-binding	59/16969	0.0240903 11	0.0480088 18	0.0159857 5	5970	+
GO:0004860	protein-kinase inhibitor-activity	60/16969	0.0244942 95	0.0480088 18	0.0159857 5	836	+

[GO..xlsx](#)

Supplementary Table 5. The data of KEGG enrichment analysis

Supplementary Material

ID	Description	Background	pvalue	p-adjust	qvalue	geneID	Count
hsa04115	p53 signaling pathway	72/8016	7.36E-08	5.42E-06	2.9E-06	BCL2/CASP8/CASP3/CYCS/CASP9/CHEK1/CCNB1	7
hsa04725	Cholinergic synapse	112/8016	8.98E-08	5.42E-06	2.9E-06	BCL2/CHRM3/FOS/ACHE/PRKCA/CHRM2/CHRM4/CHRM5	8
hsa05170	Human immunodeficiency virus-1 infection	212/8016	9.51E-08	5.42E-06	2.9E-06	BCL2/CASP8/RELA/CASP3/CYCS/CASP9/FOS/CH	10
hsa05167	Kaposi sarcoma-associated herpesvirus infection	186/8016	3.7E-07	1.39E-05	7.42E-06	VEGFA/CASP8/PTGS2/RELA/CASP3/HIF1A/CYCS/CASP9/FOS	9
hsa05222	Small cell lung cancer	92/8016	4.05E-07	1.39E-05	7.42E-06	BCL2/PTGS2/RELA/CASP3/CYCS/CASP9/RXR	7
hsa04215	Apoptosis - multiple species	32/8016	5.6E-07	1.6E-05	8.55E-06	BCL2/CASP8/CASP3/CYCS/CASP9	5
hsa04080	Neuroactive ligand-receptor interaction	340/8016	8.92E-07	2.18E-05	1.17E-05	ADRB2/CHRM3/PRSS1/ADRA1B/CHRM2/ADRA1A/GABRA1/ADRA2C/CHRNA2/CHRM4/CHRM5	11
hsa05161	Hepatitis B	162/8016	1.54E-06	3.29E-05	1.76E-05	BCL2/CASP8/RELA/CASP3/CYCS/CASP9/FOS/PRKCA	8
hsa04919	Thyroid hormone signaling pathway	119/8016	2.34E-06	4.44E-05	2.38E-05	ESR1/HIF1A/CASP9/PRKCA/RXR/NCOA1/NCOA2	7
hsa04210	Apoptosis	136/8016	5.7E-06	9.74E-05	5.22E-05	BCL2/CASP8/RELA/CASP3/CYCS/CASP9/FOS	7
hsa05162	Measles	138/8016	6.28E-06	9.76E-05	5.23E-05	BCL2/CASP8/RELA/CASP3/CYCS/CASP9/FOS	7

hsa04657	IL-17 signaling pathway	94/8016	8.27E-06	0.000117783	6.31E-05	CASP8/PTGS2/RELA/CASP3/FOS/FOSL1	6
hsa05134	Legionellosis	57/8016	1.06E-05	0.000139183	7.45E-05	CASP8/RELA/CASP3/CYCS/CASP9	5
hsa05163	Human cytomegalovirus infection	225/8016	1.76E-05	0.000215165	0.000115231	VEGFA/CASP8/PTGS2/RELA/CASP3/CYCS/CASP9/PRKCA	8
hsa05145	Toxoplasmosis	112/8016	2.27E-05	0.00025824	0.0001383	BCL2/CASP8/RELA/CASP3/CYCS/CASP9	6
hsa05164	Influenza A	170/8016	2.46E-05	0.000262954	0.000140825	CASP8/RELA/CASP3/PRSS1/CYCS/CASP9/PRKCA	7
hsa01524	Platinum drug resistance	73/8016	3.57E-05	0.000358972	0.000192247	BCL2/CASP8/CASP3/CYCS/CASP9	5
hsa04020	Calcium signaling pathway	193/8016	5.56E-05	0.000527798	0.000282662	ADRB2/CHRM3/PRKCA/ADRA1B/CHRM2/ADRA1A/CHRM5	7
hsa04915	Estrogen signaling pathway	138/8016	7.36E-05	0.000662091	0.000354582	BCL2/ESR1/FOS/PGR/NCOA1/NCOA2	6
hsa05210	Colorectal cancer	86/8016	7.87E-05	0.000672897	0.00036037	BCL2/CASP3/CYCS/CASP9/FOS	5
hsa04970	Salivary gland secretory pathway	90/8016	9.78E-05	0.00079636	0.00042649	ADRB2/CHRM3/PRKCA/ADRA1B/ADRA1A	5
hsa04261	Adrenergic signaling in cardiomyocytes	149/8016	0.000112616	0.000875333	0.000468783	BCL2/ADRB2/SCN5A/PRKCA/ADRA1B/ADRA1A	6
hsa04933	AGE-RAGE signaling pathway in diabetic complications	100/8016	0.000161202	0.000198501	0.000641857	VEGFA/BCL2/RELA/CASP3/PRKCA	5

Supplementary Material

Amyotro						
hsa0	phic	57/8	0.000	0.001	0.000	
5014	lateral	016	21032	49856	80255	BCL2/CASP3/CYCS/CASP9
	sclerosis		5	4	5	
(ALS)						
hsa0	Th17-cell	107/	0.000	0.001	0.000	
4659	differenti	801	22156	51551	81163	RELA/HIF1A/FOS/AHR/RXR
	ation	6	6	2	2	
hsa0	VEGF	59/8	0.000	0.001	0.000	
4370	signaling	016	24050	53027	81953	VEGFA/PTGS2/CASP9/PRKCA
	pathway		4	4	7	
hsa0	HIF-1	109/	0.000	0.001	0.000	
4066	signaling	801	24162	53027	81953	VEGFA/BCL2/RELA/HIF1A/PRKCA
	pathway	6	2	4	7	
hsa0	Viral	60/8	0.000	0.001	0.000	
5416	myocardi	016	25670	56775	83961	CASP8/CASP3/CYCS/CASP9
	tis		9	6	1	
hsa0	TNF	112/	0.000	0.001	0.000	
4668	signaling	801	27426	61722	86610	CASP8/PTGS2/RELA/CASP3/FOS
	pathway	6	6	7	5	
hsa0	Serotoner	115/	0.000	0.001	0.000	
4726	gie	801	31016	74305	93349	PTGS2/CASP3/PTGS1/HTR3A/PRKCA
	synapse	6	5	1		
hsa0	Tubereul	180/	0.000	0.001	0.000	
5152	osis	801	31599	74305	93349	BCL2/CASP8/RELA/CASP3/CYCS/CASP9
		6	2	1		
hsa0	Epstein-	201/	0.000	0.003	0.001	
5169	Barr	801	0.000	03132	62342	BCL2/CASP8/RELA/CASP3/CYCS/CASP9
	virus	6	56982	4	4	
infection						
Pathogen						
hsa0	ie	202/	0.000	0.003	0.001	
5130	Escherie	801	58499	03132	62342	CASP8/RELA/CASP3/CYCS/CASP9/FOS
	hia-coli	6	2	4	4	
infection						
hsa0	Proteogly	204/	0.000	0.003	0.001	
5205	cans-in	801	61628	09953	65995	VEGFA/ESR1/IGF2/CASP3/HIF1A/PRKCA
	cancer	6	2	5	4	
hsa0	Salmonel	214/	0.000	0.003	0.002	
5132	la	801	79281	87345	07442	BCL2/CASP8/RELA/CASP3/CYCS/FOS
	infection	6	2	4	6	
hsa0	Hepatitis	155/	0.001	0.005	0.003	
5160	C	801	21017	74832	07851	CASP8/RELA/CASP3/CYCS/CASP9
		6	4	7	3	

hsa05215	Prostate cancer	97/8016	0.00158571	0.00732855	0.00392480	BCL2/RELA/AR/CASP9	4
hsa04151	PI3K-Akt signaling pathway	354/8016	0.00218713	0.0096352	0.00516012	VEGFA/BCL2/IGF2/RELA/CASP9/PRKCA/CHRM2	7
hsa04928	Parathyroid hormone synthesis and secretion	106/8016	0.00219750	0.0096352	0.00516012	BCL2/FOS/PRKCA/RXR	4
hsa04923	Regulation of lipolysis in adipocytes	55/8016	0.00290397	0.01241447	0.00664856	ADRB2/PTGS2/PTGS1	3
hsa04010	MAPK signaling pathway	295/8016	0.00405268	0.01690268	0.00905222	VEGFA/IGF2/RELA/CASP3/FOS/PRKCA	6
hsa04380	Osteoclast differentiation	128/8016	0.00434316	0.01768288	0.00947005	PPARG/RELA/FOS/FOSL1	4
hsa04926	Relaxin signaling pathway	129/8016	0.00446528	0.01775728	0.00950990	VEGFA/RELA/FOS/PRKCA	4
hsa05223	Non-small-cell lung cancer	66/8016	0.00486720	0.01891571	0.01013030	CASP9/PRKCA/RXR	3
hsa05206	MicroRNA-As in cancer	310/8016	0.00516188	0.01961514	0.01050488	VEGFA/BCL2/TP63/PTGS2/CASP3/PRKCA	6
hsa04917	Prolactin signaling pathway	70/8016	0.00573863	0.02116224	0.01133342	ESR1/RELA/FOS	3
hsa05418	Fluid shear stress and atherosclerosis	139/8016	0.00581652	0.02116224	0.01133342	VEGFA/BCL2/RELA/FOS	4

Supplementary Material

hsa0 Breast 5224 cancer	147/ 801 6	0.007 07666 8	0.024 58749 4	0.013 16781 8	ESR1/FOS/PGR/NCOA1	4
hsa0 Pertussis 5133	76/ 016	0.007 21161 7	0.024 58749 4	0.013 16781 8	RELA/CASP3/FOS	3
hsa0 Pancreati 5212 e-cancer	76/ 016	0.007 21161 7	0.024 58749 4	0.013 16781 8	VEGFA/RELA/CASP9	3
Non- alcoholic hsa0 fatty liver 4932 disease (NAFLD)	149/ 801 6	0.007 41783 6	0.024 58749 4	0.013 16781 8	CASP8/RELA/CASP3/CYCS	4
hsa0 Leishma 5140 niasis	77/ 016	0.007 47689 9	0.024 58749 4	0.013 16781 8	PTGS2/RELA/FOS	3
EGFR tyrosine hsa0 kinase 1521 inhibitor resistanc e	79/ 016	0.008 02470 1	0.025 89101 5	0.013 86591 7	VEGFA/BCL2/PRKCA	3
hsa0 Taste 4742 transduct ion	83/ 016	0.009 19004 4	0.029 10180 4	0.015 58545 4	CHRM3/HTR3A/GABRA1	3
eGMP- hsa0 PKG 4022 signaling pathway PD-L1 expressio n-and	167/ 801 6	0.010 98790 8	0.033 94180 8	0.018 17751 5	ADRB2/ADRA1B/ADRA1A/ADRA2C	4
hsa0 PD-1 5235 checkpoi nt pathway in-cancer	89/ 016	0.011 11544 6	0.033 94180 8	0.018 17751 5	RELA/HIF1A/FOS	3
hsa0 Huntingt 5016 on disease	264/ 801 6	0.011 72373 6	0.035 11119 7	0.018 80378 1	PPARG/CASP8/CASP3/CYCS/CASP9	5
hsa0 Alzheim 5010 r-disease	171/ 801 6	0.011 90906 1	0.035 11119 7	0.018 80378 1	CASP8/CASP3/CYCS/CASP9	4

Endocrin							
hsa01522	98/8016	0.01441165	0.04107322	0.02199673	BCL2/ESR1/FOS	3	
resistance		7	2	9			
Choline							
hsa05231	98/8016	0.01441165	0.04107322	0.02199673	HIF1A/FOS/PRKCA	3	
metabolism in cancer		7	2	9			
Aldosterone-							
hsa04960	37/8016	0.01589521	0.04154927	0.02225169	NR3C2/PRKCA	2	
regulated sodium reabsorption			9	1			
Thyroid							
hsa05216	37/8016	0.01589521	0.04154927	0.02225169	PPARG/RXR	2	
cancer			9	1			
NF-kappa-B							
hsa04064	102/8016	0.01603656	0.04154927	0.02225169	BCL2/PTGS2/RELA	3	
signaling pathway		6	4	9	1		
Pancreatic							
hsa04972	102/8016	0.01603656	0.04154927	0.02225169	CHRM3/PRSS1/PRKCA	3	
secretion		6	4	9	1		
Chagas disease							
hsa05142	102/8016	0.01603656	0.04154927	0.02225169	CASP8/RELA/FOS	3	
(American trypanosomiasis)		6	4	9	1		
Amoebiasis							
hsa05146	102/8016	0.01603656	0.04154927	0.02225169	RELA/CASP3/PRKCA	3	
		6	4	9	1		
Toll-like							
hsa04620	104/8016	0.01688630	0.04246409	0.02274161	CASP8/RELA/FOS	3	
receptor signaling pathway		6	5		8		
C-type							
hsa04625	104/8016	0.01688630	0.04246409	0.02274161	CASP8/PTGS2/RELA	3	
lectin receptor signaling pathway		6	5		8		
KEGG.xlsx							